- In April 2024, Pyros Pharmaceuticals Inc. launched VIGPODER (vigabatrin) oral solution in the United States. This formulation is indicated as monotherapy for the treatment of infantile spasms in infants aged one month to two years, offering a new ready-to-use option for clinicians and caregivers
- In July 2023, Upsher-Smith Laboratories LLC launched VIGADRONE (vigabatrin) tablets, USP 500 mg, as a fully substitutable, AB-rated generic alternative to Sabril (vigabatrin) tablets, 500 mg, in the United States, enhancing treatment accessibility
- In March 2023, Zydus Lifesciences Limited received approval from the U.S. FDA for Vigabatrin oral solution USP, 500 mg, expanding the range of available treatment formulations for infantile spasms
- In January 2022, The FDA granted final approval for Sabril (vigabatrin) to treat infantile spasms in children aged 1 month to 2 years. Vigabatrin functions by preventing the breakdown of GABA in the brain, aiding in seizure control
- In December 2022, Cerecin received U.S. FDA approval for its Investigational New Drug (IND) application for CER-001, a novel therapy for infantile spasms. This approval grants orphan drug designation, providing eligibility for market exclusivity and financial incentives
